Cargando…
Prescription patterns of P2Y12 inhibitors following revascularization in the United States: 2013–2018
P2Y12 inhibitors (i.e., clopidogrel, prasugrel, or ticagrelor) are effective at reducing adverse cardiovascular outcomes post‐revascularization in coronary artery disease (CAD). However, the choice of a specific P2Y12 inhibitor may vary according to the patient's characteristics, and trends in...
Autores principales: | Kumar, Arun, Lutsey, Pamela L., St. Peter, Wendy L., Schommer, Jon C., Van’t Hof, Jeremy R., Rajpurohit, Abhijeet, Farley, Joel F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582679/ https://www.ncbi.nlm.nih.gov/pubmed/37466284 http://dx.doi.org/10.1111/cts.13596 |
Ejemplares similares
-
Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention
por: Kumar, Arun, et al.
Publicado: (2022) -
Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study
por: Kumar, Arun, et al.
Publicado: (2022) -
Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022) -
Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013–2018
por: Yu, Lingyan, et al.
Publicado: (2021) -
National patterns of cessation of prescription opioids among Medicare beneficiaries, 2013–2018
por: Westra, Jordan, et al.
Publicado: (2022)